Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994156796> ?p ?o ?g. }
- W2994156796 endingPage "72" @default.
- W2994156796 startingPage "63" @default.
- W2994156796 abstract "The most common pancreatic diseases in cats are pancreatitis and exocrine pancreatic insufficiency (EPI). Non-invasive methods, such as serological quantification of feline pancreatic lipase immunoreactivity (fPLI), are often used in the diagnosis of pancreatitis. Previous studies have compared fPLI concentrations with histopathology, considered to be the gold standard for diagnosis of feline pancreatitis. However, fPLI concentrations in cats suffering from pancreatic tumours were rarely described. The aim of the present study was to determine the sensitivity and specificity of an in-house enzyme-linked immunosorbent assay (ELISA) for the quantification of fPLI in serum samples based on histopathological findings in cats diagnosed with various pancreatic diseases. Pancreatic biopsy samples from 80 cats were included. Five groups were defined on the basis of pancreatic histopathology: group 1, normal pancreas; group 2, nodular hyperplasia; group 3, mild pancreatitis; group 4, marked (moderate/severe) pancreatitis; and group 5, pancreatic neoplasia. Serum samples from all cats were tested by fPLI ELISA (<3.6 μg/l normal, 3.6–5.3 μg/l questionable, >5.3 μg/l pancreatitis). In group 1 (n = 19), serum fPLI values were within the reference interval in 74% of cases and in group 2 (n = 9) in 78%. Cats with mild pancreatitis (n = 23), marked pancreatitis (n = 11) and pancreatic neoplasms (n = 18) had significantly increased fPLI concentrations compared with group 1 (P = 0.004/0.001/≤0.0001). Cats with nodular hyperplasia had significantly lower fPLI values than cats with marked pancreatitis (P = 0.048) or tumours (P = 0.002). Serum fPLI concentrations in group 3 were <3.6 μg/l (n = 6), 3.6–5.3 μg/l (n = 4) and >5.3 μg/l (n = 13). Calculated test sensitivity for mild pancreatitis was fPLI >3.5 μg/l: 73.9% and fPLI >5.3 μg/l: 56.5%. In group 4 (n = 11), seven of nine cats (77.8%) with marked purulent pancreatitis had elevated fPLI. In group 4, a sensitivity of 81.8% was detected for fPLI >3.5 μg/l and 63.6% for fPLI >5.3 μg/l. Two cats with marked non-purulent pancreatitis had elevated fPLI, while two cats with marked purulent pancreatitis had normal fPLI values (<3.6 μg/l). In group 5, one cat with pancreatic adenoma and one with pancreatic acinar carcinoma had normal fPLI concentrations. The other cats with pancreatic adenoma (solid, n = 1; cystic, n = 4) or carcinoma (solid, n = 9; cystic, n = 2) had elevated or high fPLI values (4.1 to >40 μg/l, median 21.2 μg/l), probably caused by additional inflammation. The results of the present study confirm the importance of detailed histopathological characterization for the interpretation of clinical signs and fPLI values in feline pancreatitis. Primary pancreatic neoplasms may also lead to elevated fPLI concentrations as there is concurrent pancreatitis in most cases. However, severe pancreatic diseases, such as chronic non-purulent pancreatitis or tumours without inflammation, may result in normal fPLI values." @default.
- W2994156796 created "2019-12-13" @default.
- W2994156796 creator A5003207178 @default.
- W2994156796 creator A5008327855 @default.
- W2994156796 creator A5022238099 @default.
- W2994156796 creator A5035304177 @default.
- W2994156796 creator A5047150000 @default.
- W2994156796 creator A5053254998 @default.
- W2994156796 creator A5061173652 @default.
- W2994156796 creator A5084475310 @default.
- W2994156796 date "2020-01-01" @default.
- W2994156796 modified "2023-10-14" @default.
- W2994156796 title "Histopathology and Feline Pancreatic Lipase Immunoreactivity in Inflammatory, Hyperplastic and Neoplastic Pancreatic Diseases in Cats" @default.
- W2994156796 cites W1974399139 @default.
- W2994156796 cites W2002200620 @default.
- W2994156796 cites W2009037635 @default.
- W2994156796 cites W2013908058 @default.
- W2994156796 cites W2029746271 @default.
- W2994156796 cites W2029789802 @default.
- W2994156796 cites W2046739407 @default.
- W2994156796 cites W2066334046 @default.
- W2994156796 cites W2077054776 @default.
- W2994156796 cites W2077521217 @default.
- W2994156796 cites W2079033987 @default.
- W2994156796 cites W2152587391 @default.
- W2994156796 cites W2156051203 @default.
- W2994156796 cites W2166601484 @default.
- W2994156796 cites W2190314657 @default.
- W2994156796 cites W2283104502 @default.
- W2994156796 cites W2295067715 @default.
- W2994156796 cites W2337334795 @default.
- W2994156796 cites W2463926211 @default.
- W2994156796 cites W2520463832 @default.
- W2994156796 cites W2916541053 @default.
- W2994156796 cites W2944099602 @default.
- W2994156796 cites W2986447218 @default.
- W2994156796 cites W4251652953 @default.
- W2994156796 doi "https://doi.org/10.1016/j.jcpa.2019.10.195" @default.
- W2994156796 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31955805" @default.
- W2994156796 hasPublicationYear "2020" @default.
- W2994156796 type Work @default.
- W2994156796 sameAs 2994156796 @default.
- W2994156796 citedByCount "12" @default.
- W2994156796 countsByYear W29941567962020 @default.
- W2994156796 countsByYear W29941567962021 @default.
- W2994156796 countsByYear W29941567962022 @default.
- W2994156796 countsByYear W29941567962023 @default.
- W2994156796 crossrefType "journal-article" @default.
- W2994156796 hasAuthorship W2994156796A5003207178 @default.
- W2994156796 hasAuthorship W2994156796A5008327855 @default.
- W2994156796 hasAuthorship W2994156796A5022238099 @default.
- W2994156796 hasAuthorship W2994156796A5035304177 @default.
- W2994156796 hasAuthorship W2994156796A5047150000 @default.
- W2994156796 hasAuthorship W2994156796A5053254998 @default.
- W2994156796 hasAuthorship W2994156796A5061173652 @default.
- W2994156796 hasAuthorship W2994156796A5084475310 @default.
- W2994156796 hasConcept C126322002 @default.
- W2994156796 hasConcept C142724271 @default.
- W2994156796 hasConcept C175106660 @default.
- W2994156796 hasConcept C181199279 @default.
- W2994156796 hasConcept C2775967933 @default.
- W2994156796 hasConcept C2776737053 @default.
- W2994156796 hasConcept C2777562237 @default.
- W2994156796 hasConcept C2778764654 @default.
- W2994156796 hasConcept C2779697368 @default.
- W2994156796 hasConcept C2779904517 @default.
- W2994156796 hasConcept C544855455 @default.
- W2994156796 hasConcept C55493867 @default.
- W2994156796 hasConcept C71924100 @default.
- W2994156796 hasConcept C86803240 @default.
- W2994156796 hasConcept C90924648 @default.
- W2994156796 hasConceptScore W2994156796C126322002 @default.
- W2994156796 hasConceptScore W2994156796C142724271 @default.
- W2994156796 hasConceptScore W2994156796C175106660 @default.
- W2994156796 hasConceptScore W2994156796C181199279 @default.
- W2994156796 hasConceptScore W2994156796C2775967933 @default.
- W2994156796 hasConceptScore W2994156796C2776737053 @default.
- W2994156796 hasConceptScore W2994156796C2777562237 @default.
- W2994156796 hasConceptScore W2994156796C2778764654 @default.
- W2994156796 hasConceptScore W2994156796C2779697368 @default.
- W2994156796 hasConceptScore W2994156796C2779904517 @default.
- W2994156796 hasConceptScore W2994156796C544855455 @default.
- W2994156796 hasConceptScore W2994156796C55493867 @default.
- W2994156796 hasConceptScore W2994156796C71924100 @default.
- W2994156796 hasConceptScore W2994156796C86803240 @default.
- W2994156796 hasConceptScore W2994156796C90924648 @default.
- W2994156796 hasLocation W29941567961 @default.
- W2994156796 hasLocation W29941567962 @default.
- W2994156796 hasOpenAccess W2994156796 @default.
- W2994156796 hasPrimaryLocation W29941567961 @default.
- W2994156796 hasRelatedWork W2029746271 @default.
- W2994156796 hasRelatedWork W2066334046 @default.
- W2994156796 hasRelatedWork W2088114923 @default.
- W2994156796 hasRelatedWork W2119637006 @default.
- W2994156796 hasRelatedWork W2160654156 @default.
- W2994156796 hasRelatedWork W2160716114 @default.
- W2994156796 hasRelatedWork W2166172992 @default.
- W2994156796 hasRelatedWork W2417990435 @default.